MedPath

Effect of probiotic, curcumin, and curcumin-probiotic on quality of life, anxiety, stress, and depressio

Phase 3
Recruiting
Conditions
Metabolic Syndrome.
Metabolic syndrome
E88.81
Registration Number
IRCT20220315054289N2
Lead Sponsor
Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
128
Inclusion Criteria

Aged 30 - 65 years Overweight (BMI between 25 to 29.9) or obese (BMI over 30) individuals with metabolic syndrome based on ATP III criteria
Not suffering from metabolic, endocrine, or cardiovascular disease (except diabetes, dyslipidemia, and hypertension) at baseline
Not suffering from kidney, liver, or systemic diseases at the beginning of the study
Not infected with Covid-19 or any other infections for 3 months before the study
No history of hospitalization for 3 months prior to the study
Has not used antibiotics for 3 months before beginning the study
Has not taken curcumin and probiotic supplements, or supplements for 3 months before the study

Exclusion Criteria

Pregnancy
Lactating

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Quality of Life. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: SF-36 questionnaire.;Depression, Anxiety and Stress. Timepoint: At the beginning of the study (before the intervention) and the end of the study (8 weeks after the intervention). Method of measurement: DASS-21 questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath